https://www.selleckchem.com/products/ABT-263.html
Despite HCV cure, patients remain at risk for HCC, but risk factor data for HCC following SVR are limited for Asian patients. To address this gap, we analyzed 5814 patients (5646 SVR, 168 non-SVR) from the Real-World Evidence from the Asia Liver Consortium for HCV (REAL-C) who did not have HCC or a history of HCC at baseline (pre-DAA treatment) and did not develop HCC within 6months of baseline. To assess the effect of SVR on HCC incidence, we used 14 propensity score matching [(PSM), age, sex, baseline cirrhosis, and baseline AFP] to b
Like
Comment
Share
